Natco Historical Income Statement

NATCOPHARM

1,376 38.05 2.84%

Historical analysis of Natco Pharma income statement accounts such as Gross Profit of 33 B can show how well Natco Pharma Limited performed in making a profits. Evaluating Natco Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Natco Pharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Natco Pharma Limited latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Natco Pharma Limited is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Natco Pharma Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

About Natco Income Statement Analysis

Natco Pharma Limited Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Natco Pharma shareholders. The income statement also shows Natco investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Natco Pharma Income Statement Chart

As of now, Natco Pharma's Operating Income is increasing as compared to previous years. The Natco Pharma's current EBIT is estimated to increase to about 17.8 B, while Interest Expense is projected to decrease to under 180 M.

Total Revenue Gross Profit Other Operating Expenses Operating Income

Total Revenue

Total revenue comprises all receipts Natco Pharma Limited generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Natco Pharma Limited minus its cost of goods sold. It is profit before Natco Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Natco Pharma Limited. It is also known as Natco Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Natco Pharma Limited operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Natco Pharma Limited is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most accounts from Natco Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Natco Pharma Limited current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Natco Pharma Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

	2022	2023	2024 (projected)
Interest Expense	145M	192M	180.0M
Depreciation And Amortization	1.6B	1.9B	2.0B

Interest Expense Depreciation And Amortization

Natco Pharma income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Selling And Marketing Expenses	Research Development	Discontinued Operations	Net Income From Continuing Ops	Minority Interest	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		-0.39	0.91	0.9	0.7	0.79	0.81	0.85	0.9	0.88	0.82	-0.9	0.82	0.76	0.93	0.57	0.75	-0.63	0.81	-0.74	0.62	-0.02	-0.09	0.92
Interest Expense	-0.39		-0.34	-0.32	-0.49	-0.19	-0.3	-0.31	-0.42	-0.18	-0.31	0.29	-0.29	-0.37	-0.38	-0.27	-0.59	0.65	-0.31	0.4	-0.39	-0.03	-0.12	-0.36
Total Revenue	0.91	-0.34		1.0	0.64	0.93	0.96	0.97	0.94	0.95	0.96	-0.83	0.97	0.93	0.86	0.81	0.55	-0.65	0.96	-0.68	0.8	0.0	-0.01	0.77
Gross Profit	0.9	-0.32	1.0		0.6	0.94	0.97	0.98	0.91	0.95	0.98	-0.83	0.98	0.94	0.86	0.82	0.51	-0.61	0.97	-0.67	0.82	0.03	0.02	0.76
Other Operating Expenses	0.7	-0.49	0.64	0.6		0.32	0.47	0.5	0.73	0.42	0.47	-0.46	0.47	0.5	0.57	0.56	0.75	-0.87	0.44	-0.55	0.52	0.13	0.2	0.65
Operating Income	0.79	-0.19	0.93	0.94	0.32		0.97	0.97	0.81	0.97	0.97	-0.82	0.97	0.92	0.8	0.73	0.33	-0.39	0.98	-0.59	0.78	-0.07	-0.12	0.67
Ebit	0.81	-0.3	0.96	0.97	0.47	0.97		1.0	0.84	0.93	1.0	-0.78	1.0	0.98	0.79	0.81	0.4	-0.54	1.0	-0.6	0.88	0.04	0.04	0.67
Ebitda	0.85	-0.31	0.97	0.98	0.5	0.97	1.0		0.86	0.94	1.0	-0.81	1.0	0.98	0.82	0.8	0.44	-0.56	1.0	-0.63	0.86	0.03	0.03	0.71
Cost Of Revenue	0.9	-0.42	0.94	0.91	0.73	0.81	0.84	0.86		0.85	0.84	-0.79	0.84	0.83	0.81	0.73	0.7	-0.73	0.83	-0.71	0.69	-0.13	-0.11	0.77
Total Operating Expenses	0.88	-0.18	0.95	0.95	0.42	0.97	0.93	0.94	0.85		0.93	-0.89	0.94	0.86	0.88	0.69	0.46	-0.43	0.94	-0.63	0.7	-0.05	-0.13	0.78
Income Before Tax	0.82	-0.31	0.96	0.98	0.47	0.97	1.0	1.0	0.84	0.93		-0.78	1.0	0.98	0.79	0.82	0.4	-0.54	1.0	-0.61	0.88	0.04	0.04	0.67
Total Other Income Expense Net	-0.9	0.29	-0.83	-0.83	-0.46	-0.82	-0.78	-0.81	-0.79	-0.89	-0.78		-0.79	-0.7	-0.92	-0.44	-0.64	0.38	-0.79	0.83	-0.57	0.15	0.31	-0.91
Net Income	0.82	-0.29	0.97	0.98	0.47	0.97	1.0	1.0	0.84	0.94	1.0	-0.79		0.97	0.8	0.81	0.4	-0.53	1.0	-0.61	0.87	0.03	0.03	0.68
Income Tax Expense	0.76	-0.37	0.93	0.94	0.5	0.92	0.98	0.98	0.83	0.86	0.98	-0.7	0.97		0.71	0.85	0.41	-0.61	0.97	-0.58	0.91	0.09	0.13	0.59
Selling General Administrative	0.93	-0.38	0.86	0.86	0.57	0.8	0.79	0.82	0.81	0.88	0.79	-0.92	0.8	0.71		0.5	0.63	-0.47	0.81	-0.68	0.58	-0.05	-0.15	0.92
Selling And Marketing Expenses	0.57	-0.27	0.81	0.82	0.56	0.73	0.81	0.8	0.73	0.69	0.82	-0.44	0.81	0.85	0.5		0.21	-0.72	0.79	-0.43	0.77	0.18	0.27	0.35
Research Development	0.75	-0.59	0.55	0.51	0.75	0.33	0.4	0.44	0.7	0.46	0.4	-0.64	0.4	0.41	0.63	0.21		-0.68	0.39	-0.66	0.4	0.01	-0.04	0.77
Discontinued Operations	-0.63	0.65	-0.65	-0.61	-0.87	-0.39	-0.54	-0.56	-0.73	-0.43	-0.54	0.38	-0.53	-0.61	-0.47	-0.72	-0.68		-0.51	0.49	-0.62	-0.18	-0.28	-0.52
Net Income From Continuing Ops	0.81	-0.31	0.96	0.97	0.44	0.98	1.0	1.0	0.83	0.94	1.0	-0.79	1.0	0.97	0.81	0.79	0.39	-0.51		-0.6	0.86	0.02	0.02	0.68
Minority Interest	-0.74	0.4	-0.68	-0.67	-0.55	-0.59	-0.6	-0.63	-0.71	-0.63	-0.61	0.83	-0.61	-0.58	-0.68	-0.43	-0.66	0.49	-0.6		-0.5	0.22	0.34	-0.69
Tax Provision	0.62	-0.39	0.8	0.82	0.52	0.78	0.88	0.86	0.69	0.7	0.88	-0.57	0.87	0.91	0.58	0.77	0.4	-0.62	0.86	-0.5		0.14	0.21	0.55
Interest Income	-0.02	-0.03	0.0	0.03	0.13	-0.07	0.04	0.03	-0.13	-0.05	0.04	0.15	0.03	0.09	-0.05	0.18	0.01	-0.18	0.02	0.22	0.14		0.94	-0.1
Net Interest Income	-0.09	-0.12	-0.01	0.02	0.2	-0.12	0.04	0.03	-0.11	-0.13	0.04	0.31	0.03	0.13	-0.15	0.27	-0.04	-0.28	0.02	0.34	0.21	0.94		-0.21
Reconciled Depreciation	0.92	-0.36	0.77	0.76	0.65	0.67	0.67	0.71	0.77	0.78	0.67	-0.91	0.68	0.59	0.92	0.35	0.77	-0.52	0.68	-0.69	0.55	-0.1	-0.21

Click cells to compare fundamentals

Natco Pharma Account Relationship Matchups

Natco Pharma income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	998M	1.2B	1.4B	1.6B	1.9B	2.0B
Interest Expense	162M	177M	88M	145M	192M	180.0M
Total Revenue	18.9B	16.9B	19.0B	27.1B	40.0B	42.0B
Gross Profit	13.8B	10.8B	12.2B	20.8B	31.4B	33.0B
Other Operating Expenses	14.0B	11.9B	17.6B	19.4B	14.1B	9.1B
Operating Income	4.9B	5.0B	2.2B	8.8B	26.0B	27.3B
Ebit	5.9B	5.9B	2.2B	8.8B	16.9B	17.8B
Ebitda	6.9B	7.1B	3.6B	10.4B	18.8B	19.7B
Cost Of Revenue	5.1B	6.1B	6.8B	6.3B	8.6B	9.1B
Total Operating Expenses	8.9B	5.8B	10.8B	13.1B	31.2B	32.7B
Income Before Tax	5.7B	5.8B	2.0B	8.6B	16.7B	17.6B
Total Other Income Expense Net	775M	(3.5B)	(4.9B)	(6.3B)	(9.2B)	(8.8B)
Net Income	4.6B	4.4B	1.7B	7.2B	13.9B	14.6B
Income Tax Expense	1.1B	1.4B	322M	1.5B	2.9B	3.0B
Selling General Administrative	587M	565M	818M	1.1B	1.2B	1.2B
Selling And Marketing Expenses	981M	344M	437M	961M	1.5B	1.6B
Research Development	633M	1.5B	1.8B	902M	1.2B	621.3M
Net Income From Continuing Ops	4.6B	4.4B	1.7B	7.2B	13.9B	14.6B
Net Income Applicable To Common Shares	4.6B	4.4B	1.7B	7.2B	8.2B	4.4B
Tax Provision	1.1B	1.4B	322M	1.5B	2.9B	1.6B
Interest Income	665M	133M	177M	145M	166.8M	158.4M
Net Interest Income	576M	(133M)	(177M)	(145M)	(192M)	(182.4M)
Reconciled Depreciation	998M	1.2B	1.4B	1.6B	1.9B	1.3B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Natco Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Natco Historical Income Statement

About Natco Income Statement Analysis

Natco Pharma Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Operating Income

Natco Pharma income statement Correlations

Natco Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Natco Pharma income statement Accounts

Also Currently Popular

Other Information on Investing in Natco Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebitda

Selling General Administrative	- 0.92	Total Other Income Expense Net
Reconciled Depreciation	- 0.91	Total Other Income Expense Net
Total Other Income Expense Net	- 0.9	Depreciation And Amortization
Total Other Income Expense Net	- 0.89	Total Operating Expenses
Discontinued Operations	- 0.87	Other Operating Expenses
Total Other Income Expense Net	- 0.83	Gross Profit